Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)

DRUG2 trials

Sponsors

Peking University Cancer Hospital & Institute

Conditions

Melanoma Stage IV

Phase 1

Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

Peking University Cancer Hospital & InstituteMelanoma Stage IV

Start: 2021-10-01End: 2023-12-31Target: 15Updated: 2021-10-05

Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

Peking University Cancer Hospital & InstituteMelanoma Stage IV

Start: 2021-10-01End: 2023-12-31Target: 30Updated: 2021-10-07

Related Papers

The phase 1 clinical trial of anti–PD-1 ab plus intrahepatic injection of oncolytic virus (OH2) combined radiotherapy of liver metastasis in stage IV melanoma.

Journal of Clinical Oncology2025-05-28

Axitinib in combination with anti–PD-1 ab (pucotenlimab) plus intra-hepatic injection of oncolytic virus (OH2), in patients with mucosal melanoma and liver metastasis: An open-label phase I trial.

Journal of Clinical Oncology2024-06-011 citations

The phase 1 clinical trial of anti–PD-1 (pucotenlimab) plus intrahepatic injection of oncolytic virus (OH2) combined with radiotherapy of liver metastasis in stage IV melanoma.

Journal of Clinical Oncology2023-06-01